Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and Bioavailability of GLPG3667 in Healthy Males
NCT05335447Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Apr 2022
- Primary completion
- Jun 2022
- Countries
- 1
01
Overview
Phase 1, open-label trial of cadefrecitinib in psoriasis, systemic lupus erythematosus (SLE) and dermatomyositis (DM) (2 arms), sponsored by Galapagos NV. Primary endpoints: Recovery of total radioactivity (TRA) excreted in urine expressed as a percentage of the administered dose (Ae%), Recovery of total radioactivity (TRA) excreted in feces expressed as a percentage of the administered dose (Af%) and 3 more. Started Apr 2022; status: completed.
02
Drugs
cadefrecitinib
03
Conditions
psoriasissystemic lupus erythematosus (SLE)dermatomyositis (DM)
Beyond the preview
Go deeper on NCT05335447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05335447.